Market Outlook
The global Peptide CDMO market size was valued at USD 2369.8 million in 2022 and is forecast to a readjusted size of USD 6106.7 million by 2029 with a CAGR of 14.5% during review period.
Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino terminus. This is the opposite direction of protein biosynthesis.
A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing.
CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.
Bachem is the largest player of global peptide CDMO market, holds a share over 20%, other key players include PolyPeptide, AmbioPharm, and USV Peptides, etc. In terms of type, APIs and intermediates type is the largest segment, with a share about 60%, and in terms of application, the commercial segment holds share about 80 percent.
This report is a detailed and comprehensive analysis for global Peptide CDMO market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Peptide CDMO market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2018-2029
Global Peptide CDMO market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2018-2029
Global Peptide CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2018-2029
Global Peptide CDMO market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/Ton), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Peptide CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Peptide CDMO market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Key Market Players
Bachem
PolyPeptide
AmbioPharm
USV Peptides
Thermo Fisher
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CordenPharma
CPC Scientific
Segmentation By Type
APIs and Intermediates
FDF
Segmentation By Application
Commercial
Academic Research
Segmentation By Region
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Market SWOT Analysis
What are the strengths of the Peptide CDMO Market in 2025?
The Peptide CDMO market benefits from its strong expertise in peptide synthesis, scalability, and growing demand for peptides in personalized medicine. Advancements in technology and the increasing pipeline of peptide-based drugs will drive the market's growth. Furthermore, the high flexibility in manufacturing custom peptides boosts market appeal.
What are the weaknesses in the Peptide CDMO Market in 2025?
The complexity of peptide synthesis, coupled with high production costs and the need for specialized equipment, could limit market expansion. Also, regulatory hurdles in different regions might complicate the entry of new players. Maintaining the balance between high-quality standards and cost efficiency remains a challenge.
What opportunities exist for the Peptide CDMO Market in 2025?
The surge in peptide-based therapeutic research, especially in oncology and metabolic disorders, offers significant growth opportunities. Expanding applications in vaccine development and targeted therapies also present prospects. Moreover, the rising trend of outsourcing by pharmaceutical companies to reduce operational costs is another key opportunity.
What are the threats to the Peptide CDMO Market in 2025?
Intense competition, especially from established pharmaceutical manufacturers with in-house peptide production capabilities, poses a threat to smaller CDMOs. Additionally, fluctuations in raw material prices and global supply chain disruptions could impact profitability. Regulatory changes and stringent compliance requirements also pose risks to market growth.
Market PESTEL Analysis
What political factors influence the Peptide CDMO Market in 2025?
Political stability and government policies regarding the healthcare sector, such as drug approval processes and funding for biotechnology research, directly impact the Peptide CDMO market. Furthermore, trade agreements and the regulatory environment for outsourcing and manufacturing in different regions can influence market dynamics.
How do economic factors affect the Peptide CDMO Market in 2025?
Economic factors like global healthcare spending, investment in research and development, and the cost of raw materials play a significant role. Economic downturns could lead to reduced budgets for drug development, whereas strong economic growth might encourage investments in peptide-based therapeutics, thus driving the market forward.
What social factors shape the Peptide CDMO Market in 2025?
An increasing patient demand for personalized medicine, rising awareness of peptide therapeutics, and the growing prevalence of chronic diseases (such as cancer and metabolic disorders) contribute to the market’s growth. Additionally, the expanding global healthcare infrastructure in developing regions is creating new opportunities for peptide-based drugs.
How do technological factors impact the Peptide CDMO Market in 2025?
Technological advancements in peptide synthesis, automation, and quality control are significantly improving the efficiency and scalability of production. Innovations in biotechnology and precision medicine also support the increased demand for peptides in therapeutic applications, driving growth in the market.
What environmental factors are relevant to the Peptide CDMO Market in 2025?
Environmental sustainability and regulatory pressures to reduce waste and energy consumption in manufacturing are becoming increasingly important. Peptide CDMOs must adopt greener production methods and comply with environmental regulations to stay competitive and reduce their ecological footprint.
What legal factors influence the Peptide CDMO Market in 2025?
Legal factors such as intellectual property laws, patent expirations, and regulatory compliance (FDA, EMA) are crucial in determining market success. Stringent legal frameworks around manufacturing, clinical trials, and drug approval processes can either accelerate or hinder the entry of new products into the market.
Market SIPOC Analysis
Who are the suppliers in the Peptide CDMO Market in 2025?
Suppliers include raw material providers for amino acids, solvents, and reagents, as well as specialized equipment manufacturers for peptide synthesis and purification. Additionally, contract research organizations (CROs) and logistics companies that support the supply chain for peptide production play a key role.
What inputs are required for the Peptide CDMO Market in 2025?
Inputs needed include high-quality raw materials for peptide synthesis (such as amino acids), state-of-the-art manufacturing equipment, skilled labor for production and quality control, as well as research and development data for peptide drug development. Compliance with regulatory guidelines is also a critical input for ensuring market success.
What process steps take place in the Peptide CDMO Market in 2025?
The process involves peptide synthesis, purification, and characterization. This is followed by scale-up manufacturing for clinical trials and commercial production. Key activities also include quality assurance, regulatory compliance checks, and packaging. Ongoing research and process optimization are vital for maintaining competitive advantage.
Who are the customers in the Peptide CDMO Market in 2025?
Customers include pharmaceutical companies, biotechnology firms, and academic institutions that require peptides for drug discovery, development, and clinical trials. Additionally, contract research organizations (CROs) and pharmaceutical service providers also form a significant customer base for peptide manufacturing services.
What are the expected outputs from the Peptide CDMO Market in 2025?
The outputs are high-quality, GMP-compliant peptide products, which include therapeutic peptides for oncology, metabolic disorders, and other diseases. Additionally, the market delivers custom peptides for research purposes, along with reliable contract manufacturing services that cater to the growing peptide drug pipeline.
Market Porter's Five Forces
What is the threat of new entrants in the Peptide CDMO Market in 2025?
The threat of new entrants is moderate. Although the peptide manufacturing industry requires significant capital investment in specialized equipment and compliance with stringent regulations, the increasing demand for peptide-based therapeutics may attract new players. However, barriers such as technical expertise, economies of scale, and the need for strong regulatory knowledge limit easy market entry.
How strong is the bargaining power of suppliers in the Peptide CDMO Market in 2025?
The bargaining power of suppliers is relatively high. Peptide synthesis requires specialized raw materials, such as high-quality amino acids, which are often sourced from a limited number of suppliers. Additionally, the specialized nature of the equipment and expertise required for production gives suppliers some leverage in negotiations.
What is the bargaining power of buyers in the Peptide CDMO Market in 2025?
The bargaining power of buyers is moderate to high. Pharmaceutical and biotechnology companies have the option to choose from multiple CDMOs, which creates some competitive pressure. However, the highly specialized nature of peptide production means that buyers must often rely on established manufacturers that meet regulatory and quality standards, which can limit their negotiating power.
How intense is the threat of substitute products or services in the Peptide CDMO Market in 2025?
The threat of substitutes is low. While other forms of therapeutics exist, such as small molecule drugs or monoclonal antibodies, peptides are increasingly valued for their specificity and lower toxicity. The unique advantages of peptides in treating complex diseases limit the likelihood of substitutes replacing them in the near future.
How competitive is the Peptide CDMO Market in 2025?
The market is highly competitive. Many established players, along with emerging CDMOs, are vying for market share. The demand for peptide-based therapeutics is growing, leading to increased competition in terms of cost efficiency, production capabilities, and regulatory compliance. Companies that can innovate and offer high-quality, scalable production have a distinct competitive advantage.
Market Upstream Analysis
What are the key inputs in the Peptide CDMO Market in 2025?
Key inputs include raw materials like amino acids, solvents, and reagents required for peptide synthesis. Additionally, specialized equipment for peptide production, along with skilled labor, are essential inputs. Access to cutting-edge technology for synthesis and purification also plays a critical role in the upstream process.
What are the major suppliers in the Peptide CDMO Market in 2025?
Suppliers include manufacturers of raw materials such as amino acids and other chemicals used in peptide synthesis, as well as companies providing specialized equipment for peptide production. Additionally, research institutions and technology providers that offer innovative solutions for peptide synthesis and purification are important upstream players.
What technological factors influence the upstream process in the Peptide CDMO Market in 2025?
Technological advancements in peptide synthesis methods, such as solid-phase peptide synthesis (SPPS) and liquid-phase techniques, significantly affect upstream operations. Innovations in automation, process optimization, and scale-up technologies improve production efficiency and reduce costs. Additionally, improvements in quality control and analytics are critical in maintaining high standards.
What are the regulatory and compliance challenges in the upstream process of the Peptide CDMO Market in 2025?
Regulatory challenges include compliance with Good Manufacturing Practices (GMP) and other regional regulations for peptide production. Strict adherence to quality standards is necessary, which may require additional investments in testing and validation. Navigating these regulatory landscapes, along with ensuring supply chain traceability, can pose challenges for upstream operations.
How do supply chain dynamics affect the upstream process in the Peptide CDMO Market in 2025?
Supply chain disruptions, such as fluctuations in raw material availability and pricing, can impact upstream processes. The reliance on specialized suppliers for amino acids and reagents can lead to vulnerabilities in the supply chain. Moreover, geopolitical tensions or global health crises may further strain raw material sourcing, necessitating robust risk management strategies.
Market Midstream Analysis
What are the key processes in the Midstream of the Peptide CDMO Market in 2025?
The key processes in the midstream of the peptide CDMO market include peptide synthesis, purification, and formulation. These processes involve complex techniques such as solid-phase peptide synthesis (SPPS) and liquid-phase synthesis, followed by purification methods like high-performance liquid chromatography (HPLC). The formulation process ensures peptides are prepared for drug development and clinical trials.
What are the challenges faced in the Midstream of the Peptide CDMO Market in 2025?
Challenges include maintaining high yields and purity in peptide synthesis, particularly with complex peptides that require advanced technologies. Additionally, scaling up production while ensuring regulatory compliance and consistent product quality can be difficult. The high cost of specialized equipment and skilled personnel adds to the operational complexities.
What role does quality control play in the Midstream of the Peptide CDMO Market in 2025?
Quality control is crucial in ensuring the peptides meet the required standards for clinical trials and commercialization. Rigorous testing is performed to assess purity, stability, and bioactivity. Maintaining stringent quality control measures is essential for compliance with GMP regulations and for ensuring that the peptides are safe and effective for therapeutic use.
How does technology impact the Midstream process in the Peptide CDMO Market in 2025?
Technological advancements in automation, real-time analytics, and continuous manufacturing processes are enhancing efficiency in the midstream of the peptide CDMO market. Innovations in purification and process monitoring technologies help reduce production time and costs while ensuring product consistency. Additionally, technology aids in scaling up from laboratory to commercial production.
What are the cost considerations in the Midstream of the Peptide CDMO Market in 2025?
Cost considerations include the high expense of raw materials, advanced equipment, and skilled labor required for synthesis and purification. The complexity of producing high-quality peptides at scale also impacts costs, as maintaining compliance with regulatory standards requires substantial investments in quality assurance and process validation.
Market Downstream Analysis
What are the key activities in the Downstream of the Peptide CDMO Market in 2025?
Key activities in the downstream process include the final formulation of peptides, packaging, and distribution. After the peptide synthesis and purification are completed, peptides are formulated into the desired dosage forms (such as injectable solutions or lyophilized powders) and packaged for clinical trials or commercial use. The final step involves distribution to pharmaceutical companies or research institutions.
What challenges exist in the Downstream of the Peptide CDMO Market in 2025?
Challenges in the downstream include ensuring stability and shelf-life of the peptides during storage and transport. There are also regulatory challenges associated with packaging and labeling, especially with varying requirements across different markets. Ensuring compliance with global distribution standards while managing supply chain logistics adds to the complexity.
What is the role of regulatory compliance in the Downstream of the Peptide CDMO Market in 2025?
Regulatory compliance is essential in the downstream process, as peptides must meet the regulatory standards set by authorities like the FDA, EMA, and other regional agencies. This includes adhering to Good Distribution Practices (GDP) and ensuring proper documentation for clinical trials and commercialization. Stringent regulations on labeling, packaging, and shipment must be followed to avoid costly delays and non-compliance risks.
How does the Downstream process impact the Peptide CDMO Market in 2025?
The downstream process impacts the market by ensuring that the peptides reach their intended users—pharmaceutical companies and research institutions—in the right form and condition. Efficiency in downstream processes, including timely distribution and cost-effective packaging, influences the competitiveness of CDMOs. Additionally, ensuring the integrity and quality of the final product can significantly impact customer satisfaction and market reputation.
What are the cost considerations in the Downstream of the Peptide CDMO Market in 2025?
Downstream costs are influenced by the complexities of formulation, packaging materials, and distribution logistics. Additionally, complying with stringent regulatory requirements for packaging and labeling adds to the operational expenses. Efficient distribution channels and minimizing wastage during the packaging process are essential for maintaining cost-effectiveness in the downstream process.
Chapter 1, to describe Peptide CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Peptide CDMO, with price, sales, revenue and global market share of Peptide CDMO from 2018 to 2023.
Chapter 3, the Peptide CDMO competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Peptide CDMO breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Peptide CDMO market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Peptide CDMO.
Chapter 14 and 15, to describe Peptide CDMO sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Peptide CDMO
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Peptide CDMO Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 APIs and Intermediates
1.3.3 FDF
1.4 Market Analysis by Application
1.4.1 Overview: Global Peptide CDMO Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Commercial
1.4.3 Academic Research
1.5 Global Peptide CDMO Market Size & Forecast
1.5.1 Global Peptide CDMO Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Peptide CDMO Sales Quantity (2018-2029)
1.5.3 Global Peptide CDMO Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Bachem
2.1.1 Bachem Details
2.1.2 Bachem Major Business
2.1.3 Bachem Peptide CDMO Product and Services
2.1.4 Bachem Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bachem Recent Developments/Updates
2.2 PolyPeptide
2.2.1 PolyPeptide Details
2.2.2 PolyPeptide Major Business
2.2.3 PolyPeptide Peptide CDMO Product and Services
2.2.4 PolyPeptide Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 PolyPeptide Recent Developments/Updates
2.3 AmbioPharm
2.3.1 AmbioPharm Details
2.3.2 AmbioPharm Major Business
2.3.3 AmbioPharm Peptide CDMO Product and Services
2.3.4 AmbioPharm Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 AmbioPharm Recent Developments/Updates
2.4 USV Peptides
2.4.1 USV Peptides Details
2.4.2 USV Peptides Major Business
2.4.3 USV Peptides Peptide CDMO Product and Services
2.4.4 USV Peptides Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 USV Peptides Recent Developments/Updates
2.5 Thermo Fisher
2.5.1 Thermo Fisher Details
2.5.2 Thermo Fisher Major Business
2.5.3 Thermo Fisher Peptide CDMO Product and Services
2.5.4 Thermo Fisher Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Thermo Fisher Recent Developments/Updates
2.6 Bio Basic
2.6.1 Bio Basic Details
2.6.2 Bio Basic Major Business
2.6.3 Bio Basic Peptide CDMO Product and Services
2.6.4 Bio Basic Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Bio Basic Recent Developments/Updates
2.7 JPT
2.7.1 JPT Details
2.7.2 JPT Major Business
2.7.3 JPT Peptide CDMO Product and Services
2.7.4 JPT Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 JPT Recent Developments/Updates
2.8 Genscript
2.8.1 Genscript Details
2.8.2 Genscript Major Business
2.8.3 Genscript Peptide CDMO Product and Services
2.8.4 Genscript Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Genscript Recent Developments/Updates
2.9 Xinbang Pharma
2.9.1 Xinbang Pharma Details
2.9.2 Xinbang Pharma Major Business
2.9.3 Xinbang Pharma Peptide CDMO Product and Services
2.9.4 Xinbang Pharma Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Xinbang Pharma Recent Developments/Updates
2.10 ScinoPharm
2.10.1 ScinoPharm Details
2.10.2 ScinoPharm Major Business
2.10.3 ScinoPharm Peptide CDMO Product and Services
2.10.4 ScinoPharm Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 ScinoPharm Recent Developments/Updates
2.11 SN Biopharm
2.11.1 SN Biopharm Details
2.11.2 SN Biopharm Major Business
2.11.3 SN Biopharm Peptide CDMO Product and Services
2.11.4 SN Biopharm Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 SN Biopharm Recent Developments/Updates
2.12 CBL
2.12.1 CBL Details
2.12.2 CBL Major Business
2.12.3 CBL Peptide CDMO Product and Services
2.12.4 CBL Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 CBL Recent Developments/Updates
2.13 Piramal Pharma
2.13.1 Piramal Pharma Details
2.13.2 Piramal Pharma Major Business
2.13.3 Piramal Pharma Peptide CDMO Product and Services
2.13.4 Piramal Pharma Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Piramal Pharma Recent Developments/Updates
2.14 CordenPharma
2.14.1 CordenPharma Details
2.14.2 CordenPharma Major Business
2.14.3 CordenPharma Peptide CDMO Product and Services
2.14.4 CordenPharma Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 CordenPharma Recent Developments/Updates
2.15 CPC Scientific
2.15.1 CPC Scientific Details
2.15.2 CPC Scientific Major Business
2.15.3 CPC Scientific Peptide CDMO Product and Services
2.15.4 CPC Scientific Peptide CDMO Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 CPC Scientific Recent Developments/Updates
3 Competitive Environment: Peptide CDMO by Manufacturer
3.1 Global Peptide CDMO Sales Quantity by Manufacturer (2018-2023)
3.2 Global Peptide CDMO Revenue by Manufacturer (2018-2023)
3.3 Global Peptide CDMO Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Peptide CDMO by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Peptide CDMO Manufacturer Market Share in 2022
3.4.2 Top 6 Peptide CDMO Manufacturer Market Share in 2022
3.5 Peptide CDMO Market: Overall Company Footprint Analysis
3.5.1 Peptide CDMO Market: Region Footprint
3.5.2 Peptide CDMO Market: Company Product Type Footprint
3.5.3 Peptide CDMO Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Peptide CDMO Market Size by Region
4.1.1 Global Peptide CDMO Sales Quantity by Region (2018-2029)
4.1.2 Global Peptide CDMO Consumption Value by Region (2018-2029)
4.1.3 Global Peptide CDMO Average Price by Region (2018-2029)
4.2 North America Peptide CDMO Consumption Value (2018-2029)
4.3 Europe Peptide CDMO Consumption Value (2018-2029)
4.4 Asia-Pacific Peptide CDMO Consumption Value (2018-2029)
4.5 South America Peptide CDMO Consumption Value (2018-2029)
4.6 Middle East and Africa Peptide CDMO Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Peptide CDMO Sales Quantity by Type (2018-2029)
5.2 Global Peptide CDMO Consumption Value by Type (2018-2029)
5.3 Global Peptide CDMO Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Peptide CDMO Sales Quantity by Application (2018-2029)
6.2 Global Peptide CDMO Consumption Value by Application (2018-2029)
6.3 Global Peptide CDMO Average Price by Application (2018-2029)
7 North America
7.1 North America Peptide CDMO Sales Quantity by Type (2018-2029)
7.2 North America Peptide CDMO Sales Quantity by Application (2018-2029)
7.3 North America Peptide CDMO Market Size by Country
7.3.1 North America Peptide CDMO Sales Quantity by Country (2018-2029)
7.3.2 North America Peptide CDMO Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Peptide CDMO Sales Quantity by Type (2018-2029)
8.2 Europe Peptide CDMO Sales Quantity by Application (2018-2029)
8.3 Europe Peptide CDMO Market Size by Country
8.3.1 Europe Peptide CDMO Sales Quantity by Country (2018-2029)
8.3.2 Europe Peptide CDMO Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Peptide CDMO Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Peptide CDMO Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Peptide CDMO Market Size by Region
9.3.1 Asia-Pacific Peptide CDMO Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Peptide CDMO Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Peptide CDMO Sales Quantity by Type (2018-2029)
10.2 South America Peptide CDMO Sales Quantity by Application (2018-2029)
10.3 South America Peptide CDMO Market Size by Country
10.3.1 South America Peptide CDMO Sales Quantity by Country (2018-2029)
10.3.2 South America Peptide CDMO Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Peptide CDMO Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Peptide CDMO Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Peptide CDMO Market Size by Country
11.3.1 Middle East & Africa Peptide CDMO Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Peptide CDMO Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Peptide CDMO Market Drivers
12.2 Peptide CDMO Market Restraints
12.3 Peptide CDMO Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Peptide CDMO and Key Manufacturers
13.2 Manufacturing Costs Percentage of Peptide CDMO
13.3 Peptide CDMO Production Process
13.4 Peptide CDMO Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Peptide CDMO Typical Distributors
14.3 Peptide CDMO Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Peptide CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Peptide CDMO Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Bachem Basic Information, Manufacturing Base and Competitors
Table 4. Bachem Major Business
Table 5. Bachem Peptide CDMO Product and Services
Table 6. Bachem Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Bachem Recent Developments/Updates
Table 8. PolyPeptide Basic Information, Manufacturing Base and Competitors
Table 9. PolyPeptide Major Business
Table 10. PolyPeptide Peptide CDMO Product and Services
Table 11. PolyPeptide Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. PolyPeptide Recent Developments/Updates
Table 13. AmbioPharm Basic Information, Manufacturing Base and Competitors
Table 14. AmbioPharm Major Business
Table 15. AmbioPharm Peptide CDMO Product and Services
Table 16. AmbioPharm Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. AmbioPharm Recent Developments/Updates
Table 18. USV Peptides Basic Information, Manufacturing Base and Competitors
Table 19. USV Peptides Major Business
Table 20. USV Peptides Peptide CDMO Product and Services
Table 21. USV Peptides Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. USV Peptides Recent Developments/Updates
Table 23. Thermo Fisher Basic Information, Manufacturing Base and Competitors
Table 24. Thermo Fisher Major Business
Table 25. Thermo Fisher Peptide CDMO Product and Services
Table 26. Thermo Fisher Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Thermo Fisher Recent Developments/Updates
Table 28. Bio Basic Basic Information, Manufacturing Base and Competitors
Table 29. Bio Basic Major Business
Table 30. Bio Basic Peptide CDMO Product and Services
Table 31. Bio Basic Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Bio Basic Recent Developments/Updates
Table 33. JPT Basic Information, Manufacturing Base and Competitors
Table 34. JPT Major Business
Table 35. JPT Peptide CDMO Product and Services
Table 36. JPT Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. JPT Recent Developments/Updates
Table 38. Genscript Basic Information, Manufacturing Base and Competitors
Table 39. Genscript Major Business
Table 40. Genscript Peptide CDMO Product and Services
Table 41. Genscript Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Genscript Recent Developments/Updates
Table 43. Xinbang Pharma Basic Information, Manufacturing Base and Competitors
Table 44. Xinbang Pharma Major Business
Table 45. Xinbang Pharma Peptide CDMO Product and Services
Table 46. Xinbang Pharma Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Xinbang Pharma Recent Developments/Updates
Table 48. ScinoPharm Basic Information, Manufacturing Base and Competitors
Table 49. ScinoPharm Major Business
Table 50. ScinoPharm Peptide CDMO Product and Services
Table 51. ScinoPharm Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. ScinoPharm Recent Developments/Updates
Table 53. SN Biopharm Basic Information, Manufacturing Base and Competitors
Table 54. SN Biopharm Major Business
Table 55. SN Biopharm Peptide CDMO Product and Services
Table 56. SN Biopharm Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. SN Biopharm Recent Developments/Updates
Table 58. CBL Basic Information, Manufacturing Base and Competitors
Table 59. CBL Major Business
Table 60. CBL Peptide CDMO Product and Services
Table 61. CBL Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. CBL Recent Developments/Updates
Table 63. Piramal Pharma Basic Information, Manufacturing Base and Competitors
Table 64. Piramal Pharma Major Business
Table 65. Piramal Pharma Peptide CDMO Product and Services
Table 66. Piramal Pharma Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Piramal Pharma Recent Developments/Updates
Table 68. CordenPharma Basic Information, Manufacturing Base and Competitors
Table 69. CordenPharma Major Business
Table 70. CordenPharma Peptide CDMO Product and Services
Table 71. CordenPharma Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. CordenPharma Recent Developments/Updates
Table 73. CPC Scientific Basic Information, Manufacturing Base and Competitors
Table 74. CPC Scientific Major Business
Table 75. CPC Scientific Peptide CDMO Product and Services
Table 76. CPC Scientific Peptide CDMO Sales Quantity (Tons), Average Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. CPC Scientific Recent Developments/Updates
Table 78. Global Peptide CDMO Sales Quantity by Manufacturer (2018-2023) & (Tons)
Table 79. Global Peptide CDMO Revenue by Manufacturer (2018-2023) & (USD Million)
Table 80. Global Peptide CDMO Average Price by Manufacturer (2018-2023) & (US$/Ton)
Table 81. Market Position of Manufacturers in Peptide CDMO, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 82. Head Office and Peptide CDMO Production Site of Key Manufacturer
Table 83. Peptide CDMO Market: Company Product Type Footprint
Table 84. Peptide CDMO Market: Company Product Application Footprint
Table 85. Peptide CDMO New Market Entrants and Barriers to Market Entry
Table 86. Peptide CDMO Mergers, Acquisition, Agreements, and Collaborations
Table 87. Global Peptide CDMO Sales Quantity by Region (2018-2023) & (Tons)
Table 88. Global Peptide CDMO Sales Quantity by Region (2024-2029) & (Tons)
Table 89. Global Peptide CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 90. Global Peptide CDMO Consumption Value by Region (2024-2029) & (USD Million)
Table 91. Global Peptide CDMO Average Price by Region (2018-2023) & (US$/Ton)
Table 92. Global Peptide CDMO Average Price by Region (2024-2029) & (US$/Ton)
Table 93. Global Peptide CDMO Sales Quantity by Type (2018-2023) & (Tons)
Table 94. Global Peptide CDMO Sales Quantity by Type (2024-2029) & (Tons)
Table 95. Global Peptide CDMO Consumption Value by Type (2018-2023) & (USD Million)
Table 96. Global Peptide CDMO Consumption Value by Type (2024-2029) & (USD Million)
Table 97. Global Peptide CDMO Average Price by Type (2018-2023) & (US$/Ton)
Table 98. Global Peptide CDMO Average Price by Type (2024-2029) & (US$/Ton)
Table 99. Global Peptide CDMO Sales Quantity by Application (2018-2023) & (Tons)
Table 100. Global Peptide CDMO Sales Quantity by Application (2024-2029) & (Tons)
Table 101. Global Peptide CDMO Consumption Value by Application (2018-2023) & (USD Million)
Table 102. Global Peptide CDMO Consumption Value by Application (2024-2029) & (USD Million)
Table 103. Global Peptide CDMO Average Price by Application (2018-2023) & (US$/Ton)
Table 104. Global Peptide CDMO Average Price by Application (2024-2029) & (US$/Ton)
Table 105. North America Peptide CDMO Sales Quantity by Type (2018-2023) & (Tons)
Table 106. North America Peptide CDMO Sales Quantity by Type (2024-2029) & (Tons)
Table 107. North America Peptide CDMO Sales Quantity by Application (2018-2023) & (Tons)
Table 108. North America Peptide CDMO Sales Quantity by Application (2024-2029) & (Tons)
Table 109. North America Peptide CDMO Sales Quantity by Country (2018-2023) & (Tons)
Table 110. North America Peptide CDMO Sales Quantity by Country (2024-2029) & (Tons)
Table 111. North America Peptide CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 112. North America Peptide CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 113. Europe Peptide CDMO Sales Quantity by Type (2018-2023) & (Tons)
Table 114. Europe Peptide CDMO Sales Quantity by Type (2024-2029) & (Tons)
Table 115. Europe Peptide CDMO Sales Quantity by Application (2018-2023) & (Tons)
Table 116. Europe Peptide CDMO Sales Quantity by Application (2024-2029) & (Tons)
Table 117. Europe Peptide CDMO Sales Quantity by Country (2018-2023) & (Tons)
Table 118. Europe Peptide CDMO Sales Quantity by Country (2024-2029) & (Tons)
Table 119. Europe Peptide CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Peptide CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Peptide CDMO Sales Quantity by Type (2018-2023) & (Tons)
Table 122. Asia-Pacific Peptide CDMO Sales Quantity by Type (2024-2029) & (Tons)
Table 123. Asia-Pacific Peptide CDMO Sales Quantity by Application (2018-2023) & (Tons)
Table 124. Asia-Pacific Peptide CDMO Sales Quantity by Application (2024-2029) & (Tons)
Table 125. Asia-Pacific Peptide CDMO Sales Quantity by Region (2018-2023) & (Tons)
Table 126. Asia-Pacific Peptide CDMO Sales Quantity by Region (2024-2029) & (Tons)
Table 127. Asia-Pacific Peptide CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 128. Asia-Pacific Peptide CDMO Consumption Value by Region (2024-2029) & (USD Million)
Table 129. South America Peptide CDMO Sales Quantity by Type (2018-2023) & (Tons)
Table 130. South America Peptide CDMO Sales Quantity by Type (2024-2029) & (Tons)
Table 131. South America Peptide CDMO Sales Quantity by Application (2018-2023) & (Tons)
Table 132. South America Peptide CDMO Sales Quantity by Application (2024-2029) & (Tons)
Table 133. South America Peptide CDMO Sales Quantity by Country (2018-2023) & (Tons)
Table 134. South America Peptide CDMO Sales Quantity by Country (2024-2029) & (Tons)
Table 135. South America Peptide CDMO Consumption Value by Country (2018-2023) & (USD Million)
Table 136. South America Peptide CDMO Consumption Value by Country (2024-2029) & (USD Million)
Table 137. Middle East & Africa Peptide CDMO Sales Quantity by Type (2018-2023) & (Tons)
Table 138. Middle East & Africa Peptide CDMO Sales Quantity by Type (2024-2029) & (Tons)
Table 139. Middle East & Africa Peptide CDMO Sales Quantity by Application (2018-2023) & (Tons)
Table 140. Middle East & Africa Peptide CDMO Sales Quantity by Application (2024-2029) & (Tons)
Table 141. Middle East & Africa Peptide CDMO Sales Quantity by Region (2018-2023) & (Tons)
Table 142. Middle East & Africa Peptide CDMO Sales Quantity by Region (2024-2029) & (Tons)
Table 143. Middle East & Africa Peptide CDMO Consumption Value by Region (2018-2023) & (USD Million)
Table 144. Middle East & Africa Peptide CDMO Consumption Value by Region (2024-2029) & (USD Million)
Table 145. Peptide CDMO Raw Material
Table 146. Key Manufacturers of Peptide CDMO Raw Materials
Table 147. Peptide CDMO Typical Distributors
Table 148. Peptide CDMO Typical Customers
List of Figures
Figure 1. Peptide CDMO Picture
Figure 2. Global Peptide CDMO Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Peptide CDMO Consumption Value Market Share by Type in 2022
Figure 4. APIs and Intermediates Examples
Figure 5. FDF Examples
Figure 6. Global Peptide CDMO Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Peptide CDMO Consumption Value Market Share by Application in 2022
Figure 8. Commercial Examples
Figure 9. Academic Research Examples
Figure 10. Global Peptide CDMO Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Peptide CDMO Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Peptide CDMO Sales Quantity (2018-2029) & (Tons)
Figure 13. Global Peptide CDMO Average Price (2018-2029) & (US$/Ton)
Figure 14. Global Peptide CDMO Sales Quantity Market Share by Manufacturer in 2022
Figure 15. Global Peptide CDMO Consumption Value Market Share by Manufacturer in 2022
Figure 16. Producer Shipments of Peptide CDMO by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 17. Top 3 Peptide CDMO Manufacturer (Consumption Value) Market Share in 2022
Figure 18. Top 6 Peptide CDMO Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Global Peptide CDMO Sales Quantity Market Share by Region (2018-2029)
Figure 20. Global Peptide CDMO Consumption Value Market Share by Region (2018-2029)
Figure 21. North America Peptide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 22. Europe Peptide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 23. Asia-Pacific Peptide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 24. South America Peptide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 25. Middle East & Africa Peptide CDMO Consumption Value (2018-2029) & (USD Million)
Figure 26. Global Peptide CDMO Sales Quantity Market Share by Type (2018-2029)
Figure 27. Global Peptide CDMO Consumption Value Market Share by Type (2018-2029)
Figure 28. Global Peptide CDMO Average Price by Type (2018-2029) & (US$/Ton)
Figure 29. Global Peptide CDMO Sales Quantity Market Share by Application (2018-2029)
Figure 30. Global Peptide CDMO Consumption Value Market Share by Application (2018-2029)
Figure 31. Global Peptide CDMO Average Price by Application (2018-2029) & (US$/Ton)
Figure 32. North America Peptide CDMO Sales Quantity Market Share by Type (2018-2029)
Figure 33. North America Peptide CDMO Sales Quantity Market Share by Application (2018-2029)
Figure 34. North America Peptide CDMO Sales Quantity Market Share by Country (2018-2029)
Figure 35. North America Peptide CDMO Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 37. Canada Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Mexico Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Europe Peptide CDMO Sales Quantity Market Share by Type (2018-2029)
Figure 40. Europe Peptide CDMO Sales Quantity Market Share by Application (2018-2029)
Figure 41. Europe Peptide CDMO Sales Quantity Market Share by Country (2018-2029)
Figure 42. Europe Peptide CDMO Consumption Value Market Share by Country (2018-2029)
Figure 43. Germany Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. France Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. United Kingdom Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Russia Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Italy Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Asia-Pacific Peptide CDMO Sales Quantity Market Share by Type (2018-2029)
Figure 49. Asia-Pacific Peptide CDMO Sales Quantity Market Share by Application (2018-2029)
Figure 50. Asia-Pacific Peptide CDMO Sales Quantity Market Share by Region (2018-2029)
Figure 51. Asia-Pacific Peptide CDMO Consumption Value Market Share by Region (2018-2029)
Figure 52. China Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Japan Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Korea Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. India Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Southeast Asia Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Australia Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. South America Peptide CDMO Sales Quantity Market Share by Type (2018-2029)
Figure 59. South America Peptide CDMO Sales Quantity Market Share by Application (2018-2029)
Figure 60. South America Peptide CDMO Sales Quantity Market Share by Country (2018-2029)
Figure 61. South America Peptide CDMO Consumption Value Market Share by Country (2018-2029)
Figure 62. Brazil Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Argentina Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Middle East & Africa Peptide CDMO Sales Quantity Market Share by Type (2018-2029)
Figure 65. Middle East & Africa Peptide CDMO Sales Quantity Market Share by Application (2018-2029)
Figure 66. Middle East & Africa Peptide CDMO Sales Quantity Market Share by Region (2018-2029)
Figure 67. Middle East & Africa Peptide CDMO Consumption Value Market Share by Region (2018-2029)
Figure 68. Turkey Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Egypt Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Saudi Arabia Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. South Africa Peptide CDMO Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Peptide CDMO Market Drivers
Figure 73. Peptide CDMO Market Restraints
Figure 74. Peptide CDMO Market Trends
Figure 75. Porters Five Forces Analysis
Figure 76. Manufacturing Cost Structure Analysis of Peptide CDMO in 2022
Figure 77. Manufacturing Process Analysis of Peptide CDMO
Figure 78. Peptide CDMO Industrial Chain
Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 80. Direct Channel Pros & Cons
Figure 81. Indirect Channel Pros & Cons
Figure 82. Methodology
Figure 83. Research Process and Data Source
